Immunophenotyping

Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Saturday, November 4, 2023
Survival, UCB, NAM, Immune reconstitution inflammatory syndrome, Therapy, CD57, MD, Infection, Cell, SITC, Immunotherapy, B cell, Science, NF, Immunophenotyping, Annual general meeting, Kinetics, Culture, Society, Cancer, Patient, CF, Non-Hodgkin lymphoma, Fibroblast, Myelocyte, Pharmaceutical industry, Vaccine, NK

(Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in San Diego, CA.

Key Points: 
  • (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today shared new data on the impact of the company’s proprietary nicotinamide (NAM) technology on its allogeneic stem cell therapy omidubicel and investigational natural killer (NK) cell therapy candidate GDA-201 at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in San Diego, CA.
  • Both omidubicel and GDA-201 are powered by Gamida Cell’s proprietary NAM technology, which enhances and expands cells to create potentially curative cell therapies for patients with cancer.
  • Omidubicel was approved under the brand name Omisirge™ (omidubicel-onlv) by the U.S. FDA in April 2023 for allogeneic stem cell transplant; GDA-201 is in Phase 1 study for the treatment of non-Hodgkin lymphoma (NCT05296525).
  • Data on the first three cohorts of the Phase 1 study of GDA-201 were recently reported.

Lineage to Present at 2023 AAPS National Biotechnology Conference

Retrieved on: 
Tuesday, April 18, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Doctor of Philosophy, AAPS, Genentech, Immunophenotyping, Intellia Therapeutics, TASE, NYSE American, Lineage Cell Therapeutics, Therapy, Clinical pharmaceutical scientist, Conference, Pharmaceutical industry

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference , on April 25th, 2023 at 10:00 am Eastern Time, as part of “The Evolution of Cellular Therapy Symposium,” moderated by Sebastian Guelman, Ph.D., Senior Principal Scientist, Genentech, Inc.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage’s Chief Executive Officer, will present at the 2023 American Association of Pharmaceutical Scientists (AAPS) National Biotechnology Conference , on April 25th, 2023 at 10:00 am Eastern Time, as part of “The Evolution of Cellular Therapy Symposium,” moderated by Sebastian Guelman, Ph.D., Senior Principal Scientist, Genentech, Inc.
  • The “Advances in Therapeutic Development Across Modalities” panel, will also feature presenters from Intellia Therapeutics and Takeda Pharmaceutical Company Ltd., who will be discussing the rapid advancement of technologies and practices for monitoring exposure, immunophenotyping, and clinical endpoints around cellular modalities as well as considerations around allogeneic versus autologous cell therapies.
  • The 2023 AAPS National Biotechnology Conference is taking place at the Philadelphia Marriott Downtown Hotel, April 23-26, 2023.

Sysmex Inostics and Genomic Testing Cooperative Form Partnership to Accelerate Therapeutic Discovery and Development

Retrieved on: 
Thursday, April 13, 2023
Chromosome, DNA, CE, Partnership, AACR, TMB, Hematology, HRD, CAP, NGS, Clinical trial, Liquid biopsy, Cancer, Licensure, RNA, Immunophenotyping, GTC, CLIA, MD, Patient, Blood, HPV, Artificial intelligence, Liquid, NYS, EBV, Sysmex Corporation, Vaccine, Pharmaceutical industry

The partnership synergizes GTC's proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next generation sequencing (NGS) profiling, with Sysmex Inostics's global commercial capabilities in biopharma therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.

Key Points: 
  • The partnership synergizes GTC's proprietary genomic databases, technology in artificial intelligence (AI), and DNA and RNA next generation sequencing (NGS) profiling, with Sysmex Inostics's global commercial capabilities in biopharma therapeutic development and ultra-sensitive Plasma-Safe-SeqS technology.
  • Shinichi Sato, president, and Chief Executive Officer of Sysmex Inostics, stated, "Our new relationship with GTC extends our commitment to our biopharma partners.
  • We understand not one testing solution fits all stages of therapeutic development and it was imperative to offer our biopharma partners GTC's broader panels for their discovery work."
  • "The alliance with Sysmex Inostics is fundamental to our mission of democratizing genomic testing and making it available and affordable to every patient dealing with cancer.

Cytek® Biosciences Introduces New 20-Color AML Panel

Retrieved on: 
Tuesday, March 7, 2023
Aurora, MRD, Acquisition, AML, Cell, Flow cytometry, Drug discovery, Immune system, Immunophenotyping, Medical imaging

FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid Leukemia (AML) Panel.

Key Points: 
  • FREMONT, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the launch of a new 20-Color Acute Myeloid Leukemia (AML) Panel.
  • A new single-tube flow panel for the development of AML therapies, this pre-optimized assay allows researchers to quickly and efficiently run AML analysis on any Cytek® Aurora or Northern Lights™ system equipped with violet, blue and red lasers.
  • Multiparametric flow cytometry assays are widely used in detecting and monitoring AML in drug discovery, translational research and clinical trials.
  • Cytek’s 20-Color AML Panel is an effective and sensitive flow cytometric approach for identifying and characterizing normal and aberrant cells, immunophenotyping, and evaluating measurable residual disease (MRD) in AML samples.

$8 Billion Worldwide Flow Cytometry Industry to 2027 - Featuring Agilent Technologies, Apogee Flow Systems, BD and Enzo Life Sciences Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, January 20, 2023
Research, Science, Flow cytometry, Artificial intelligence, Diagnosis, Cell, Cell membrane, COVID-19, Micelle, Protein, HIV-AIDS, Cancer, Growth, Co-production (public services), Prevalence, R, Immunophenotyping, Disease, Biotechnology, Necrosis, Microscope, Vaccine

Flow cytometry refers to a biophysical and laser-based analytical technology that is used in the analysis of the cells or micelles that are usually suspended in a fluid using a laser beam.

Key Points: 
  • Flow cytometry refers to a biophysical and laser-based analytical technology that is used in the analysis of the cells or micelles that are usually suspended in a fluid using a laser beam.
  • This technique aids in subclassifying cell types and detecting residual levels of disease through probes to develop the best treatment plan for the patient.
  • The increasing prevalence of chronic medical ailments, such as HIV-AIDS and cancer, is one of the key factors driving the growth of the market.
  • Furthermore, the widespread adoption of stem cell therapy is also enhancing the utilization of flow cytometry.

Global Cell Cytometry Market Report 2022 to 2035: Players Include Agilent, Beckton Dickinson, Beckman Coulter Life Sciences and Bio-Rad - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 20, 2022
Biotechnology, Health, Science, Stem Cells, Research, Partnership, Sartorius, Luminescence, Research, Geography, Expansion microscopy, Biomarker, Growth, Type, Particle-size distribution, Agilent Technologies, Thermo Fisher Scientific, Q5, Patent, Immunophenotyping, Library, Cell, Proteomics, Renewable energy, Mobile phone, Microscope, Compact Disc, Fine chemical

Novel cell cytometry devices have recently emerged as crucial analytical and visualization tools that have revolutionized the global cell cytometry industry.

Key Points: 
  • Novel cell cytometry devices have recently emerged as crucial analytical and visualization tools that have revolutionized the global cell cytometry industry.
  • What are the key value drivers in the global cell cytometry market, focusing on high throughput flow cytometers and image cytometers?
  • What is the current / future market size of global cell cytometry market, focusing on high throughput flow cytometers and image cytometers?
  • Who are the key players engaged in the global cell cytometry market, focusing on high through flow cytometers and image cytometers?

PathAI to Present on AI Models Supporting Advances in Oncology Research at Society for Immunotherapy of Cancer Annual Meeting

Retrieved on: 
Monday, November 7, 2022
Science, Biotechnology, Research, Oncology, Health, Artificial Intelligence, Technology, Clinical Trials, Diagnosis, Patient, Society, Precision medicine, Deep learning, Stomach, Immunotherapy, Melanoma, Cancer, GNN, CD8, Machine learning, Hepatocellular carcinoma, Large-cell lung carcinoma, SITC, Squamous cell carcinoma, Drug development, Pancreatic cancer, Immunophenotyping, ML, Head, Pathology, Colorectal cancer, Neoplasm, Cell, Cholangiocarcinoma, Research, Tumor microenvironment, Medical device, Medical imaging, Pathai, NSCLC

PathAI has since expanded upon that research and will share data demonstrating how their newly developed ML-based models quantify CD8+ lymphocytes and CD8 topology classifiers across seven cancer types: NSCLC, urothelial carcinoma, head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma.

Key Points: 
  • PathAI has since expanded upon that research and will share data demonstrating how their newly developed ML-based models quantify CD8+ lymphocytes and CD8 topology classifiers across seven cancer types: NSCLC, urothelial carcinoma, head and neck squamous cell carcinoma, gastric cancer, colorectal cancer, pancreatic cancer, and hepatocellular carcinoma.
  • Our latest results support and further extend our research in immuno-oncology for multiple disease areas, said Dr. Mike Montalto, Chief Scientific Officer at PathAI.
  • This is another big step forward in innovating and improving pathology research, future drug development, and, ultimately, patient outcomes.
  • Additionally, PathAI has developed a new deep-learning-based method for the analysis of whole slide image multiplex immunofluorescence (mIF) data in NSCLC.

Applications of Cryopreserved Human Dissociated Tumor Cells (DTCs) for Drug and Diagnostic Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, October 24, 2022
DTC -Yukemuri Junjou Hen- from High&Low, Immunophenotyping, Research, Tissue, Isoplexis, Tumor microenvironment, Acquisition, Doctor of Philosophy, Industry, Cryopreservation, Flow cytometry, Food, Biomarker, Medical imaging

TORONTO, Oct. 24, 2022 /PRNewswire-PRWeb/ -- The acquisition of fresh human tissue is often an impediment to significant research advances. As an alternative, Discovery Life Sciences offers cryopreserved human dissociated tumor cells (DTCs) and tissues as a viable specimen source for many downstream applications, including immunophenotyping, bulk and single-cell sequencing, and single-cell functionality. Extensive cellular profiling of DTCs by flow cytometry revealed indication-specific trends in the composition of the tumor microenvironment. Additionally, these specimens provide the opportunity to screen for novel biomarker expressions including the expression patterns of the programmed cell death protein-1/ programmed cell death ligand-1 (PD1/PDL1) pathway.

Key Points: 
  • In this free webinar, explore the applications of cryopreserved human dissociated tumor cells (DTCs) for drug and diagnostic development.
  • Attendees will learn about the generation of the world's largest cryopreserved dissociated tumor biobank for large scale biomarker discovery programs.
  • Register to learn about the applications of cryopreserved human dissociated tumor cells (DTCs) for drug and diagnostic development.
  • For more information, or to register for this event, visit Applications of Cryopreserved Human Dissociated Tumor Cells (DTCs) for Drug and Diagnostic Development .

PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Retrieved on: 
Monday, September 26, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Technology, Other Technology, YouTube, PerkinElmer, Software, Workflow, Process validation, List of life sciences, Safety, ESG, Twitter, NYSE, Immunophenotyping, Antibody, Company, LinkedIn, Image Cytometry Standard, Government, Decision-making, Automation, CQA, Instagram, PKI, Science, Calibration, Food, Research, MX, Flow cytometry, Informatics, Fine chemical, Facebook

To further streamline the customer experience, optimized reagent kits with validated antibodies from PerkinElmers BioLegend business are also part of the proprietary solution.

Key Points: 
  • To further streamline the customer experience, optimized reagent kits with validated antibodies from PerkinElmers BioLegend business are also part of the proprietary solution.
  • The new offering provides researchers expanded cell sample CQA analysis options beyond flow cytometry and staining methods, which historically have required a variety of different instruments and analytical methods.
  • "Pharmaceutical companies have invested heavily in cell and gene therapy, but they struggle to assess the complex cell samples required to meet immense scientific demands and regulatory rigor across their research and manufacturing processes," said Alan Fletcher, senior vice president, Life Sciences, PerkinElmer.
  • PerkinElmers Nexcelom unit is a leading provider of automated cell counting technology and image cytometry products for cell analysis, including the original and widely adopted Cellaca MX high-throughput automated cell counter.

Alpha Tau Announces the Acceptance in Major Peer-Reviewed Journals (International Journal of Radiation Oncology, Biology, Physics, and Frontiers in Oncology) of Two Landmark Pre-Clinical Studies Demonstrating Significant Potential Synergies Between the Al

Retrieved on: 
Thursday, September 8, 2022
Neoplasm, Squamous cell carcinoma, COVID-19, Glioblastoma, Technology, GBM, Frontiers, XV, Research, Alpha Sigma Tau, Immunity, Immunophenotyping, MDSC, Brain, Trial of the century, Time, Xi, Gene expression, Canadian International Council, ASTRO, Risk, Mouse, Society, Biology, Blood, VEGF, DNA repair, DNA, SEC, U.S. Securities and Exchange Commission, SCC, Pembrolizumab, 100,000, PD-1, TMZ, GLOBE, CD31, Nasdaq, FDA, Immune system, American Society for Radiation Oncology, Cell death, Cell proliferation, RNA transfection, Annual report, Private Securities Litigation Reform Act, CTO, Vii, Alpha Tau Delta, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Oncology, Bevacizumab, Physics, Radiation therapy, Tel Aviv University, Alpha

JERUSALEM, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau") (Nasdaq: DRTS and DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, announced today the acceptance of two landmark pre-clinical studies in major peer-reviewed journals, both demonstrating the significant potential synergies between Alpha DaRT therapy and standard-of-care solid tumor therapies used today.

Key Points: 
  • We are very excited to have these fantastic results recognized by two leading journals in our field, said Alpha Tau CEO Uzi Sofer.
  • We also are impressed by the synergies we see with other mechanisms such as anti-angiogenesis and continue to explore those in parallel as well.
  • These results demonstrate potential synergies with immune stimulation in mice and support the further exploration of the Alpha DaRT as a compelling local radiation therapy with the potential to induce antitumor immunity.
  • In this pre-clinical study, Squamous Cell Carcinoma (SCC) tumor-bearing mice were treated with Alpha DaRT in combination with an anti-PD1 therapy (aPD-1).